SCHEMBL5158700

SCHEMBL5158700

CCC(=O)c1cccc(F)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.44
PDK2 Q15119 1/20 0.43
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
ALDH1A1 P00352 1/20 0.42
ALOX15 P16050 1/20 0.42
BCHE P06276 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
ERCC5 P28715 2/20 0.41
FEN1 P39748 2/20 0.41
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
ALB P02768 1/20 0.40
PTPN1 P18031 1/20 0.40
PBRM1 Q86U86 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12467964 0.86 ALDH1A1 (0.46) CES2CES1ALDH1A1ALOX15BCHE
SCHEMBL31444508 0.81 PTPN1 (0.49) CES2CES1ALDH1A1ALOX15BCHE
SCHEMBL31599609 0.81 CES2 (0.61) RXFP1PDK2CES2CES1ALDH1A1
SCHEMBL2255346 0.81 ERCC5 (0.61) PDK2CES2CES1ALDH1A1MEN1
SCHEMBL633282 0.81 CES2 (0.61) RXFP1PDK2CES2CES1ALDH1A1
SCHEMBL1155949 0.80 PTPN1 (0.58) RXFP1CES2CES1ALDH1A1ALOX15
SCHEMBL30036725 0.80 PTPN1 (0.58) RXFP1CES2CES1ALDH1A1ALOX15
SCHEMBL10769427 0.79 HSP90AB1 (0.47) PDK2ALDH1A1MEN1KMT2AERCC5
SCHEMBL4598039 0.79 ALB (0.60) RXFP1PDK2CES2CES1ALDH1A1
SCHEMBL28823305 0.79 NLRP3 (0.49) ALDH1A1ALOX15MEN1KMT2AERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102947300-B Alkaloid amino ester derivative and pharmaceutical composition thereof 奇斯药制品公司 2016-09-21 CN disclosed
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 US disclosed
US-20090192138-A1 COMPOUNDS BAESCHLIN DANIEL KASPAR 2009-07-30 US disclosed
EP-1790337-A2 Methods and compounds for treating depression and other disorders NPS PHARMACEUTICALS, INC. (US) 2007-05-30 EP disclosed
EP-1096926-B1 METHODS AND COMPOUNDS FOR TREATING DEPRESSION NPS PHARMA INC (US) 2007-02-28 EP disclosed
US-20040039014-A1 Methods and compounds for treating depression and other disorders NPS PHARMACEUTICALS, INC. 2004-02-26 US disclosed
EP-1096926-A2 METHODS AND COMPOUNDS FOR TREATING DEPRESSION NPS PHARMACEUTICALS, INC. (US) 2001-05-09 EP disclosed
WO-2000002551-A2 METHODS AND COMPOUNDS FOR TREATING DEPRESSION NPS PHARMACEUTICALS, INC. (US) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192138-A1 COMPOUNDS DPP4, DPP3, DPP8 RXFP1 984/4885PDK2 430/4885CES2 141/4885
US-20040039014-A1 Methods and compounds for treating depression and other disorders GRIN1, GRIN2C, GRIN3B RXFP1 774/4885PDK2 2128/4885CES2 937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.